Literature DB >> 19801106

Proton beam radiotherapy versus three-dimensional conformal stereotactic body radiotherapy in primary peripheral, early-stage non-small-cell lung carcinoma: a comparative dosimetric analysis.

O Kenneth Macdonald1, Jon J Kruse, Janelle M Miller, Yolanda I Garces, Paul D Brown, Robert C Miller, Robert L Foote.   

Abstract

PURPOSE: Proton radiotherapy (PT) and stereotactic body radiotherapy (SBRT) have the capacity to optimize the therapeutic ratio. We analyzed the dosimetric differences between PT and SBRT in treating primary peripheral early-stage non-small-cell lung cancer. METHODS AND MATERIALS: Eight patients were simulated, planned, and treated with SBRT according to accepted techniques. SBRT treatments were retrospectively planned using heterogeneity corrections. PT treatment plans were generated using single-, two-, and three-field passively scattered and actively scanned proton beams. Calculated dose characteristics were compared.
RESULTS: Comparable planning target volume (PTV) median minimum and maximum doses were observed between PT and SBRT plans. Higher median maximum doses 2 cm from the PTV were observed for PT, but higher median PTV doses were observed for SBRT. The total lung mean and V5 doses were significantly lower with actively scanned PT. The lung V13 and V20 were comparable. The dose to normal tissues was lower with PT except to skin and ribs. Although the maximum doses to skin and ribs were similar or higher with PT, the median doses to these structures were higher with SBRT. Passively scattered plans, compared with actively scanned plans, typically demonstrated higher doses to the PTV, lung, and organs at risk.
CONCLUSIONS: Single-, two-, or three-field passively or actively scanned proton therapy delivered comparable PTV dose with generally less dose to normal tissues in these hypothetic treatments. Actively scanned beam plans typically had more favorable dose characteristics to the target, lung, and other soft tissues compared with the passively scanned plans. The clinical significance of these findings remains to be determined.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19801106     DOI: 10.1016/j.ijrobp.2009.04.023

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  25 in total

1.  Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer.

Authors:  Arya Amini; Katherine Ciura; James Welsh; Ngoc Nguyen; Matt Palmer; Pamela K Allen; Michael Paolini; Zhongxing Liao; Jaques Bluett; Radhe Mohan; Daniel Gomez; James D Cox; Ritsuko Komaki; Joe Y Chang
Journal:  Med Dosim       Date:  2013       Impact factor: 1.482

2.  Giving oligometastases the best shot using stereotactic body radiosurgery with image guidance. How far is the cat out of the bag?

Authors:  Johnny Yap
Journal:  J Gastrointest Oncol       Date:  2010-09

3.  Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer.

Authors:  Joe Y Chang; Wencheng Zhang; Ritsuko Komaki; Noah C Choi; Shen Chan; Daniel Gomez; Michael O'Reilly; Melenda Jeter; Michael Gillin; Xiaorong Zhu; Xiaodong Zhang; Radhe Mohan; Stephen Swisher; Stephen Hahn; James D Cox
Journal:  Radiother Oncol       Date:  2017-01-28       Impact factor: 6.280

Review 4.  Proton therapy for thoracic reirradiation of non-small cell lung cancer.

Authors:  Hann-Hsiang Chao; Abigail T Berman
Journal:  Transl Lung Cancer Res       Date:  2018-04

5.  Proton SBRT for medically inoperable stage I NSCLC.

Authors:  Kenneth D Westover; Joao Seco; Judith A Adams; Michael Lanuti; Noah C Choi; Martijn Engelsman; Henning Willers
Journal:  J Thorac Oncol       Date:  2012-06       Impact factor: 15.609

Review 6.  Comparison of particle beam therapy and stereotactic body radiotherapy for early stage non-small cell lung cancer: A systematic review and hypothesis-generating meta-analysis.

Authors:  Alexander Chi; Haiquan Chen; Sijin Wen; Haijuan Yan; Zhongxing Liao
Journal:  Radiother Oncol       Date:  2017-05-22       Impact factor: 6.280

Review 7.  Proton Therapy in Non-small Cell Lung Cancer.

Authors:  Shane Mesko; Daniel Gomez
Journal:  Curr Treat Options Oncol       Date:  2018-11-27

Review 8.  Proton therapy for non-small cell lung cancer: the road ahead.

Authors:  Eric D Brooks; Matthew S Ning; Vivek Verma; X Ronald Zhu; Joe Y Chang
Journal:  Transl Lung Cancer Res       Date:  2019-09

Review 9.  Advanced radiation techniques for locally advanced non-small cell lung cancer: intensity-modulated radiation therapy and proton therapy.

Authors:  Nikhil Yegya-Raman; Wei Zou; Ke Nie; Jyoti Malhotra; Salma K Jabbour
Journal:  J Thorac Dis       Date:  2018-08       Impact factor: 2.895

10.  Dosimetric comparison of protons vs photons in re-irradiation of intracranial meningioma.

Authors:  Robert Poel; Anja Stuessi Lobmaier; Nicolaus Andratschke; Jan Unkelbach; Stephanie Tanadini-Lang; Matthias Guckenberger; Robert Foerster
Journal:  Br J Radiol       Date:  2019-07-02       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.